Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Income from Continuing Operations (2017 - 2025)

UroGen Pharma's Income from Continuing Operations history spans 9 years, with the latest figure at 26364000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 29.72% year-over-year to 26364000.0; the TTM value through Dec 2025 reached 153494000.0, down 20.98%, while the annual FY2025 figure was 153494000.0, 20.98% down from the prior year.
  • Income from Continuing Operations reached 26364000.0 in Q4 2025 per URGN's latest filing, up from 33347000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 21879000.0 in Q3 2023 to a low of 49940000.0 in Q2 2025.
  • Average Income from Continuing Operations over 5 years is 30160750.0, with a median of 28422000.0 recorded in 2021.
  • Peak YoY movement for Income from Continuing Operations: skyrocketed 32.74% in 2021, then tumbled 49.51% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 28452000.0 in 2021, then dropped by 1.47% to 28869000.0 in 2022, then increased by 9.88% to 26016000.0 in 2023, then tumbled by 44.19% to 37512000.0 in 2024, then grew by 29.72% to 26364000.0 in 2025.
  • Per Business Quant, the three most recent readings for URGN's Income from Continuing Operations are 26364000.0 (Q4 2025), 33347000.0 (Q3 2025), and 49940000.0 (Q2 2025).